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Introduction
The "immune escape", also known as immunoedit-
ing, is evolutionary developed ability of cancer cells
to avoid elimination by the immune system [1-3].
The main strategies used, such as ignorance,
impaired antigen presentation, expression of
immunosuppressive factors and molecules, toler-
ance induction and apoptosis resistance allow tumor
cells to grow and develop [3]. The current efforts
are focused on the identification of the molecular
mechanisms responsible for the inhibition of apop-
totic signals and sensitization of cancer cells to nat-
ural cell death induction by metabolic inhibitors.
Among various tested compounds also naturally
derived substance such as parthenolide is consid-
ered as promising agent for future anti-cancer
immunotherapy. 
Parthenolide - multifunctional naturally
derived compound
Sesquiterpene lactones are isolated from extracts of
Mexican-Indian plants and have been widely used in
indigenous medical practices, including treatment of
migraines [4,5], inflammation [6], stomachache,
toothache, menstrual irregularities, fever and rheumatoid
arthritis [7]. Parthenolide is the principal component of
sesquiterpene lactones present in medical plants such as
feverfew (Tanacetum parthenium) [8]. PN contains an α-
methylene-γ-lactone ring and an epoxide, which are able
to interact readily with nucleophilic sites of biological
molecules [9]. However, modern studies revealed that
PN has also anti-microbial, anti-inflammatory and anti-
cancer activities, which may depend on a wide range of
PN-stimulated intracellular signals [10,11]. The review
describes the postulated molecular mechanism of PN-
mediated anti-tumor activity.
Parthenolide inhibits NF-κB activation
NF-κB transcription factor is a ubiquitously expressed
transcription factor that regulates several vital func-
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tions i. e. it controls apoptosis, cell proliferation and
differentiation and is a major player in the control of
immune response and inflammation [12]. NF-κB is
activated in response to several proapoptotic stimuli,
such as TNF-α, cytotoxic drugs [14], ionizing radia-
tions [15] and oxidative stress [16]. In response to
these stimuli, NF-κB translocates to the nucleus and
regulates the expression of antiapoptotic genes. These
antiapoptotic targets include those coding for TNF-α
receptor associated factor 1 (TRAF1) and TRAF2,
cIAPs, manganese superoxide dismutase (MnSOD),
A20 and IEX-1L [15,17-19]. Moreover, NF-κB also
controls the expression of Bfl-1/A1 and Bcl-xL, two
antiapoptotic proteins from Bcl-2 family [20].
A number of experimental data indicate that the
NF-κB is involved in the development or progression
of human cancers:
1. The v-rel oncogene of the reticuloendotheliosis
virus T (Rev-T) was the first member of the
Rel/NF-κB family to be discovered. It is a trans-
forming gene and young chicken injected with the
Rev-T virus develop aggressive lymphomas [21].
2. Several members of the NF-κB and IκB families
were derived from genes that are amplified or
translocated in human caners. All these genetic
events lead to increased NF-κB transcriptional
activity, thus indicating that NF-κB target genes
might control important steps for cellular transfor-
mation or cancer progression. It was reported that
NF-κB may control not only apoptosis and cell
cycle progression, but also invasion and metastasis
[22,23].
3. More recently, NF-κB constitutive activity was
observed in various tumors, such as Hodgkin's dis-
ease [24], colon cancer [25], breast cancer [26] and
others.
The inhibition of NF-κB in cancer cells has become
one of the major strategies in anticancer therapy. The
well documented inhibitor of this transcription factor
is parthenolide. According to numerous data PN is the
inhibitor of IκB kinases complex (IKC), with the sus-
tained cytoplasmic retention of NF-κB. Multisubunit
IKC complex consists of a two proteins IKKα and
IKKβ [27]. IKKβ is essential modulator/IKKγ com-
plex-associated protein attached to NF-κB, which also
binds to NF-κB-inducing kinase (NIK) [28]. Also
MAP3 kinase NIK was identified as a direct IKK acti-
vator [29]. Similarly, MEKK1 was found to interact
and activate both of IKKs [30]. There are contradicto-
ry data concerning the direct target of PN action in
IKC complex. Kwok et al. [31] synthesized the PN
affinity reagent and showed its direct binding to IKKβ,
the kinase subunit known to play a critical role in
cytokine-mediated signaling. Mutation of cysteine 179
in the activation loop of IKKβ abolished sensitivity
towards PN. Moreover, the authors showed that PN's
in vitro and in vivo anti-inflammatory activity is medi-
ated through the α-methylene γ-lactone moiety shared
by other sesquiterpene lactones. Additionally, Saadane
et al. [32] found that the inhibition of IKKβ resulted in
stabilization of cytoplasmic IKKα, which in turn leads
to inhibition of NF-κB translocation. In contrast, Hehn-
er et al. [28] speculated that PN interferes with IKC
component that is necessary for the sequential transmis-
sion of signals leading to the activation of both IKKs.
Since the IKC is non-functional in the absence of NK-
κB essential modulator/IKKγ, this latter protein was the
potential candidate for the inhibitory activity of
parthenolide. Moreover, in all cases, the PN administra-
tion blocked DNA-binding of NF-κB. Consequently,
lack of NF-κB activity render cancer cells prone to
undergo apoptosis or became sensitized to cytokine- and
anti-cancer drug-induced cell death [33-36].
Parthenolide suppresses STATs activity
The signal transducer and activator of transcription
(STAT) proteins are extracellular ligand-responsive
transcription factors that mediate broadly diverse bio-
logical functions, such as cell proliferation, transfor-
mation, apoptosis, differentiation, fetal development,
inflammation and immune response [37]. At present,
seven STATs have been identified in mammals: STAT-
1, STAT-2, STAT-3, STAT-4, STAT-5a, STAT-5b and
STAT-6. The cytokine or growth factor stimulation
resulted in the tyrosine phosphorylation of STATs, fol-
lowed by dimerization and the subsequent gene regu-
lation via their direct binding to the DNA consensuses.
Many tyrosine kinases, including JAKs (Janus kinas-
es), TYKs (tyrosine kinases), RTKs (receptor tyrosine
kinases) and other non-RTKs can phosphorylate
STATs. In normal cells, STAT tyrosine phosphoryla-
tion is transient, lasting from 30 minutes to several
hours. However, in numerous cancer-derived cell lines
or in a primary tumors, STATs, especially STAT-3, are
persistently tyrosine phosphorylated either as a conse-
quence of deregulated positive effectors of STATs acti-
vation, such as upstream tyrosine kinases (JAK, TYK)
or repression of negative regulators of STATs phos-
phorylation, e.g. phosphatases, suppressors of
cytokine signaling (SOCS) or protein inhibitors of
activated STATs (PIAS) [38]. Constitutively activated
STATs have been observed for example in leukemia,
multiple myeloma, breast cancer, prostate cancer, col-
orectal cancer, hepatocellular carcinoma, skin cancer
and others [39-43]. The products of STATs-regulated
gene transcription, including Bcl-xL and survivin [44]
allow cancer cells to proliferate and to inhibit apopto-
sis. Therefore, the compounds having property to
inhibit STATs in cancer cells have been intensively
tested. Among them, the strong candidate for future
anti-cancer therapy is parthenolide. 
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According to Sobota et al. [45], in human hepato-
carcinoma HepG2 cells STAT-3 activation is the con-
sequence of IL-6-type cytokine action (IL-6, LIF,
OSM, IL-11, CT-1 and CNTF). The IL-6 type
cytokines signaling pathway leads to activation in
HepG2 cells of liver-derived acute phase proteins
(APPs) such as ACT (α1-antichymotrypsin) [46]. The
presence of parthenolide efficiently inhibited the IL-6-
induced up-regulation of ACT mRNA. Further analy-
sis revealed that parthenolide effect was achieved by
blocking of STAT-3 and STAT-1 binding to the regula-
tory elements in DNA. Furthermore, PN inhibited
binding of STAT-3 due to the inhibition of OSM-
induced phosphorylation of tyrosine 705 residue. This
prevented STAT-3 dimerization, a step required for its
translocation to the nucleus and subsequent gene acti-
vation. The authors hypothesized that PN inhibits
JAKs through conjugation with their SH groups. This
supposition supported the results obtained in the pres-
ence of β-mercaptoethanol (βME) since this reducing
agent restored responsiveness to cytokines most likely
by preventing interaction of parthenolide with SH
groups of target proteins [45]. 
Another cytokine which mediates its signal through
STATs is IL-4. In IL-4-stimulated endothelial cells the
STAT-6-dependent gene transcription occurs [47].
However, the parthenolide administration inhibited
STAT-6 DNA-binding activity in IL-4-treated cells and
inhibited the IL-4-driven activation of a luciferase
reporter gene under the control of STAT-6-responsive
elements. Interestingly, the authors reported that PN
did not interfere with the immediate IL-4-induced
phosphorylation of endothelial STAT-6 on its tyrosine
residue 641 and with tyrosine phosphorylation of the
adapter molecule, JAK2 - both processes are obligato-
ry for dimerization and nuclear translocation of STAT-
6. It is possible that the target for PN in the JAK/STAT
pathway is cell specific. Finally, the ability of
parthenolide to inhibit STATs action was confirmed by
Legendre et al. [48], who used PN as an experimental
inhibitor of STAT-1 and STAT-3 in articular chondro-
cytes.
The role of JNK in parthenolide-mediated
regulation of cell death
JNK is one of the MAPK (mitogen activated protein
kinases) group, together with ERKs, p38 and ERK5
[49]. All MAPKs are activated by dual phosphoryla-
tion on threonine and tyrosine motifs within the acti-
vation loop. Once activated, they translocate to the
nucleus and phosphorylate target transcription factors,
such as c-Jun. One of the potent JNK pathway activa-
tor is UV. It is rather controversial in regard to the
exact role of JNK in UV-mediated apoptosis. For
instance, JNK has been shown to be required for UV-
induced apoptotic cell death in mouse embryonic
fibroblast [50], while others demonstrated the anti-
apoptotic role of JNK in UV-induced apoptosis [51].
Interestingly, Won et al. [52] showed that partheno-
lide inhibited JNK activation and led to sensitization of
JB6 murine epidermal cells to UVB-induced apopto-
sis, suggesting antiapoptotic role of JNK in this sys-
tem. Moreover, PN appeared as a potent inhibitor of
p38 activation, what also corresponded with sensitiza-
tion to UVB-induced cell death. Eventually, the PN-
elicited sensitization of JB6 cells to UVB-induced
apoptosis was twice as strong as with the individual
JNK and p38 inhibitor. The opposite results concern-
ing the influence of parthenolide on JNK activity were
demonstrated by Zhang et al. [35]. The authors exam-
ined the TNF-α-dependent activation of JNK in
human nasopharyngeal carcinoma CNE1 cell line.
They found that PN sensitizes CNE1 cells to TNF-α-
induced apoptosis. The observed effect was the conse-
quence of described above PN-mediated inhibition of
TNF-α-induced NF-κB activation. However, the
authors proposed novel mechanism, based on limited
assembly of IKK complex with TNF-R1. On the other
hand, the PN and JNK interaction has been explained.
For the first time, Zhang et al. [35] described the dura-
tion of JNK activation in TNF-α-exposed cells. In
accordance with previous studies published by Tang et
al. [53] and Varfolomeev et al. [54] the authors con-
cluded that sustained JNK activation resulted from
NF-κB inhibition. More important, based on the obser-
vations that PN alone induces a certain degree of JNK
activation it appeared that PN itself activates JNK
activation through a TNF-α receptor independent
pathway. Similar observations of PN-mediated pro-
longed JNK activity were described by Shanmugam et
al. [55] in prostate cancer cells. 
However, despite of analogous results the final
molecular mechanism for the observed JNK activation
by PN has not been described yet. It should be empha-
sized that differential influence of PN on JNK activity
in murine epithelial cells vs. cancer cells might be use-
ful in clinical practice. Based on the literature data, it
seems that in normal cells PN protects cells from apop-
tosis, whereas in cancer cells it supports immune sys-
tem- or anti-cancer drug-induced cell death.
Oxidative stress-mediated parthenolide action
and its effect on mitochondrial activity
Oxidative stress refers to the cellular status with
enhanced production of intracellular reactive oxygen
species (ROS) and/or impaired function of the cellular
anti-oxidant defense system [56]. The intracellular
redox status is a precise balance between oxidative
stress and endogenous thiol buffering system. It
includes a great deal of non-protein low-molecular
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weight molecules, such as glutathione (GSH), as well
as several protein thiols, such as thioredoxin. It has
been shown that the intracellular redox status play an
important role in survival and cell death [57]. Many
cancer therapeutics are apoptosis inducers as they can
disrupt the redox balance by depleting the intracellular
thiol buffer system through the extrusion [58] or redis-
tribution of GSH. The unbalanced intracellular redox
state thus triggers the downstream cellular events, such
as alternation of mitochondrial function and cell sig-
naling pathways, which all lead to apoptotic cell death
[35]. 
According to several studies, parthenolide modu-
lates redox homeostasis and enables progression into
cell death. In colorectal cancer cells PN depletes intra-
cellular GSH and protein thiols in a time and dose-
dependent manner [35]. Moreover, PN significantly
enhanced the intracellular ROS and cytosolic calcium
levels, and induced ER stress. Pretreatment of colorec-
tal cancer cells with N-acetyl-L-cystein (NAC) dimin-
ished intracellular ROS and calcium levels and pro-
tected cells from PN-induced apoptosis. Moreover, the
use of GSH synthesis inhibitor - buthionine sulfox-
imine (BSO), caused a further depletion (more than
50%) of GSH and sensitized cells to PN-induced apop-
tosis. The finding that BSO alone does not induce
apoptosis suggests that the intracellular GSH plays a
critical role in parthenolide-induced apoptosis. This
supposition is supported by the results published by
Wen et al. [59], who demonstrated that parthenolide
action is due to the glutathione depletion. Bearing in
mind that mitochondrial respiratory chain is the major
production site of intracellular ROS both mitochondr-
ial integrity and its proper function are essential and
are often subject to the adverse effects of oxidative
stress. Zhang et al. [60] examined the influence of PN
on mitochondria function in colorectal cancer cells.
They found that PN activated caspases, dissipated the
mitochondrial membrane potential and released the
mitochondrial proapoptotic proteins, such as
cytochrome c and Smac/DIABLO. The confirmation
of mitochondrial (intrinsic) cell death pathway induc-
tion was the caspase-8-processed cleavage of Bid to
tBid protein after PN administration. tBid has
proapoptotic activity closely related to other Bcl-2
family members. There are two possible ways of tBid-
induced mitochondrial dysfunction: translocation and
oligomerization of tBid on mitochondrial membrane,
which causes the release of cytochrome c [61], or acti-
vates other proteins, such as Bax and Bak [62]. In col-
orectal cancer cells the conformational changes of Bax
and up-regulated level of Bak proteins were observed.
All these changes of proapoptotic Bcl-2 family mem-
bers lead to mitochondrial dysfunction and apoptosis
induction. The PN-mediated apoptosis and the role of
oxidative stress were also evaluated by Wang et al.
[63]. In multiple myeloma cells (MM) PN was able to
initiate apoptosis. The detailed analysis showed that
the PN susceptibility was determined by the catalase
activity, the potent cellular H2O2 scavenger enzyme.
The low level of catalase activity was detected in MM
cell line, while the high activity of this enzyme in nor-
mal cells protected cells from PN-induced apoptosis.
Contradictory to previous results, Wang et al. [63] did
not observe any changes in Bcl-xL or JNK action.
Next evidence for ROS-dependent PN action was
demonstrated by Zunino et al. [64] in pre-B acute
lymphoblastic leukemia (ALL) cells. In ALL cells
parthenolide induced rapid apoptotic cell death distin-
guished by the loss of nuclear DNA, externalization of
cell membrane phosphatidylserine and depolarization
of mitochondrial membranes. Using reactive oxygen
species-specific dyes an increase in nitric oxide and
superoxide anion radical was detected after 4 hours
exposure to PN. In two, from all tested MM cell lines,
also the elevated level of hypochloride anion was
detected [64]. 
It is clear that PN affects several cellular pathways
and the modulation of redox state seems to be the effi-
cient treatment for anti-cancer therapy.
Parthenolide specifically affects malignant
cells
Studies of intensive immunotherapy revealed several
metabolic inhibitors, such as cycloheximide [65], acti-
nomycin D [66], anisomycin, harringtonine [67] and
other metabolic inhibitors, which are able to modulate
the resistance of various cancer cells to cytokine-
induced cell death. However, the clinical use of sever-
al tumor cell death promoting agents is limited,
because they act non-specifically and are often cyto-
toxic. In turn, due to its low toxicity PN seems to be
the ideal agent in the future anti-cancer immunothera-
py. Described above PN-mediated effects on JNK
activity could be both pro- or antiapoptotic. It should
be emphasized that PN action in normal cells aug-
ments cells viability and protects them from UVB-
[52] or ROS-induced apoptosis [59,63,68]. In contrast,
PN is toxic to abnormal cells. The good example of
dual PN activity was presented by Guzman et al. [69].
It was shown that PN preferentially targets leukemia
cells while sparing normal hematopoetic cells. The
viability of acute myelogenous leukemia cells (AML)
and chronic myelogenous leukemia cells was greatly
reduced after PN administration. It was estimated, that
viability was more than 10-fold less that of the normal
hematopoetic controls. Noteworthy, the analogous
analysis concerning the progenitor and stem cells
(myeloid or lymphoid lineages) confirmed lack of PN
cytotoxic effect on normal cells and specific anti-can-
cer action.
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Summary
Herein, the various molecular mechanisms of proapop-
totic action of sesquiterpene lactone parthenolide on
cancer cells were described. On the transcriptional
level, PN affects both NF-κB and STATs transcription
factors activity. The up- or down-regulation of specif-
ic genes results in the elimination of antiapoptotic pro-
teins such as survivin, cIAP, Bcl-xL and/or additional
ROS generation and intrinsic apoptotic pathway
induction (Fig. 1). All these cellular changes help to
restore the natural processes of cancer cell deletion.
Additionally, the presented in vitro and in vivo studies
showed that parthenolide specifically affects malig-
nant but is harmless to normal cells. Thus, partheno-
lide should be seriously considered as potent candidate
to facilitate anticancer treatment or an adjuvant in
novel immunotherapy.
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